SEngine Precision Medicine Receives New York State CLEP Approval for PARIS® Test
07 mars 2023 12h04 HE
|
SEngine Precision Medicine, Inc.
From a single sample taken from a patient’s tumor, SEngine scientists can discover which drugs or combinations of drugs are most effective in killing or disabling that individual’s cancerSEngine now...
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
27 sept. 2022 14h58 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS® Test
07 sept. 2022 14h42 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more...
SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments
28 juil. 2022 07h00 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it...
SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
08 févr. 2022 12h30 HE
|
SEngine Precision Medicine, Inc.
SEATTLE and DIJON, France, Feb. 08, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D...
SEngine Precision Medicine Announces New Collaboration to Bring PARIS® Test to Patients with CNS Cancers
10 nov. 2021 14h40 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients...
SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe
05 oct. 2021 13h39 HE
|
SEngine Precision Medicine, Inc.
SEATTLE and PARIS, Oct. 05, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and the Institute Gustave Roussy, a leading comprehensive cancer center in Europe, today announced the execution of a...
PARIS® Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
13 sept. 2021 15h17 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer...
Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting
08 juin 2021 08h00 HE
|
SEngine Precision Medicine, Inc.
SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived tumor organoids employing its CLIA-certified PARIS® Test,...
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS® Test at 2021 ASCO Annual Meeting
29 avr. 2021 09h00 HE
|
SEngine Precision Medicine
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today...